Ypsomed Holding AG
YPSN
Classement en actions
#2948
Ypsomed Holding AG, together with its subsidiaries, develops, manufactures, and... Ypsomed Holding AG, together with its subsidiaries, develops, manufactures, and sells injection and infusion systems for safe and simple self-medication companies. The company operates through three segments: Ypsomed Delivery Systems, Ypsomed Diabetes Care, and Others. The Ypsomed Delivery Systems segment provides various injection systems, such as pen injectors, auto-injectors, and wearable injectors, as well as other smart devices. This segment offers its products under the YDS brand. The Ypsomed Diabetes Care segment sells and trades in insulin pumps, infusion sets, pen needles, blood glucose monitoring systems, accessories, and other day-to-day items for diabetics. This segment offers its products under the mylife brand name. The company offers precision turned parts; and contract manufacturing and other services. It markets its products through pharmaceutical partners, as well as through its own distribution network and independent distributors. It operates in Switzerland, Europe, North America, and internationally. Ypsomed Holding AG was founded in 1984 and is headquartered in Burgdorf, Switzerland.
Prix de l'action
$469.39
Capitalisation boursière
$6.17B
Changement (1 jour)
1.63%
Changement (1 an)
18.98%
Pays
CH
Échange Ypsomed Holding AG (YPSN)
Catégorie
Healthcare
Revenus pour Ypsomed Holding AG (YPSN)
Revenus en Oct 2026 TTM : 0
Selon les derniers rapports financiers de Ypsomed Holding AG, le chiffre d'affaires actuel de l'entreprise (TTM) est de 0. En 2026, l'entreprise a réalisé un chiffre d'affaires de 0 égal à le chiffre d'affaires de l'année 2026, qui était de 0. Le chiffre d'affaires correspond au revenu total généré par la vente de biens ou de services. Contrairement au bénéfice, aucune dépense n'est déduite.
Historique des revenus pour Ypsomed Holding AG de 2002 à 2026
Revenus à la fin de chaque année
| Année | Revenus | Changez |
|---|---|---|
| 2025 | $847.04M | 39.34% |
| 2024 | $607.88M | 11.82% |
| 2023 | $543.61M | 7.97% |
| 2022 | $503.49M | 17.75% |
| 2021 | $427.58M | 4.29% |
| 2020 | $409.99M | -10.08% |
| 2019 | $455.95M | -6.76% |
| 2018 | $489.00M | 25.91% |
| 2017 | $388.37M | 10.90% |
| 2016 | $350.19M | 10.82% |
| 2015 | $316.01M | 1.22% |
| 2014 | $312.21M | 21.22% |
| 2013 | $257.56M | -6.31% |
| 2012 | $274.90M | 3.86% |
| 2011 | $264.69M | 9.99% |
| 2010 | $240.64M | 0.57% |
| 2009 | $239.28M | -17.28% |
| 2008 | $289.26M | 26.94% |
| 2007 | $227.87M | -4.32% |
| 2006 | $238.15M | 17.72% |
| 2005 | $202.31M | 38.65% |
| 2004 | $145.92M | 43.99% |
| 2003 | $101.34M | 69.52% |
| 2002 | $59.78M | 0.00% |
Revenus d’entreprises similaires ou concurrentes
| Entreprise | Revenus | Différence de revenus | Pays |
|---|---|---|---|
| $6.04B | - |
IE
|
|
| - | - |
CN
|
|
| - | - |
CH
|
|
| - | - |
CN
|
|
| $352.16M | - |
KR
|
